GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eisai Co Ltd (OTCPK:ESALF) » Definitions » EV-to-EBIT

Eisai Co (Eisai Co) EV-to-EBIT

: 19.05 (As of Today)
View and export this data going back to . Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Eisai Co's Enterprise Value is $10,051 Mil. Eisai Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $528 Mil. Therefore, Eisai Co's EV-to-EBIT for today is 19.05.

The historical rank and industry rank for Eisai Co's EV-to-EBIT or its related term are showing as below:

ESALF' s EV-to-EBIT Range Over the Past 10 Years
Min: -2306.92   Med: 7.63   Max: 810.41
Current: 19.05

During the past 13 years, the highest EV-to-EBIT of Eisai Co was 810.41. The lowest was -2306.92. And the median was 7.63.

ESALF's EV-to-EBIT is ranked worse than
56.59% of 668 companies
in the Drug Manufacturers industry
Industry Median: 16.995 vs ESALF: 19.05

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Eisai Co's Enterprise Value for the quarter that ended in Dec. 2023 was $13,393 Mil. Eisai Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $528 Mil. Eisai Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 3.94%.


Eisai Co EV-to-EBIT Historical Data

The historical data trend for Eisai Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eisai Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-EBIT
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.11 16.46 37.13 25.52 43.00

Eisai Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,394.85 43.00 40.58 30.05 26.24

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Eisai Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eisai Co EV-to-EBIT Distribution

For the Drug Manufacturers industry and Healthcare sector, Eisai Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Eisai Co's EV-to-EBIT falls into.



Eisai Co EV-to-EBIT Calculation

Eisai Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=10051.481/527.506
=19.05

Eisai Co's current Enterprise Value is $10,051 Mil.
Eisai Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $528 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eisai Co  (OTCPK:ESALF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Eisai Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=527.506/13392.923
=3.94 %

Eisai Co's Enterprise Value for the quarter that ended in Dec. 2023 was $13,393 Mil.
Eisai Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $528 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eisai Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Eisai Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Eisai Co (Eisai Co) Business Description

Traded in Other Exchanges
Address
4-6-10 Koishikawa, Bunkyo-ku, Tokyo, JPN, 112-8088
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of a pharmaceutical business and other businesses. The pharmaceutical business is categorized by region, including Japan, Americas, China, Asia, and Europe, Middle East, and Africa. Eisai also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived by its Japanese pharmaceutical business, followed by its Americas pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.